Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Swing for the Fences – LDL-C as the Power Hitter
Extra Innings – Sustaining Victory Beyond the First Game
Turning the Double Play – Comprehensive Secondary Prevention
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
CKD-aP or Something Else? Decoding the Diagnosis